RxDoctor Payments Data

Karen Richards-Reynolds

Family · McDonough, GANPI 1699927681

Payments from drug & device makers

$823in general payments, 2019–2025

Across 51 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$115
  • Lilly USA, LLC$112
  • Biohaven Pharmaceuticals, Inc.$90
  • AstraZeneca$79
  • Amarin Pharma, Inc.$68
  • Novo Nordisk$42
  • plus $316 from 14 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$823 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$95,050
Medicare patients
214
Services billed
3,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$167,500
MounjaroTirzepatide30$47,275
JanuviaSitagliptin Phosphate40$45,373
FarxigaDapagliflozin Propanediol24$36,685
TrulicityDulaglutide27$28,013
JardianceEmpagliflozin23$26,650
LinzessLinaclotide18$18,805
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$11,739
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,257
SymbicortBudesonide/Formoterol Fumarate12$3,565
Albuterol Sulfate HfaAlbuterol Sulfate93$2,677
Gabapentin94$2,112
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,973
Levothyroxine Sodium230$1,940
Atorvastatin Calcium323$1,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$42$167,500127 claims
Lilly USA, LLCMounjaro, Trulicity$112$75,28957 claims
MerckJanuvia$12$45,37340 claims
AstraZenecaFarxiga, Symbicort$79$40,25036 claims
Boehringer IngelheimJardiance$19$26,65023 claims
AbbVieLinzess$13$18,80518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →